Drug Profile
Fampridine immediate-release
Alternative Names: 4-Aminopyridine immediate release; 4-AP - Neurorecovery; 4-AP IR; Ampydin IR; Fampridine IRLatest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Neurorecovery
- Class Aminopyridines; Neuroprotectants; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Guillain-Barre syndrome
Most Recent Events
- 31 Dec 2023 Discontinued - Phase-II for Guillain-Barre syndrome in USA (PO)
- 12 Feb 2008 Suspended - Phase-II for Guillain-Barre syndrome in USA (PO)
- 05 Feb 2008 Acorda Therapeutics acquires ownership of Neurorecovery's fampridine immediate-release product